Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7645327 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL8326095 | 0.98 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL6716017 | 0.95 | L3MBTL1 (0.45) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL8421338 | 0.95 | PTGS2 (0.48) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL8321067 | 0.86 | POLB (0.47) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL9829521 | 0.86 | ALDH1A1 (0.50) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL7093072 | 0.85 | KDM4E (0.37) | KDM4EALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL8325647 | 0.84 | KMT2A (0.40) | KDM4EALDH1A1MEN1KMT2APTGS2 | |
| SCHEMBL7111544 | 0.79 | TSHR (0.50) | KDM4EALDH1A1MEN1KMT2APOLB | |
| SCHEMBL8318661 | 0.79 | SLC29A1 (0.44) | ALDH1A1MEN1KMT2APTGS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282394-B1 | USE OF N,N'-DIBENZYL ETHYLENE DIAMINE N,N'-DIACETIC ACID DERIVATIVES AS ANTI-POLLUTION AGENT | OREAL (FR) | 2004-09-29 | — | — | EP | claimed |
| US-20040039059-A1 | Use of n,n' -dibenzyl ethylene diamine-n, n'- diacetic acid derivatives as anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | claimed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | claimed |
| US-20010016592-A1 | Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | L'OREAL S.A. | 2001-08-23 | — | — | US | claimed |
| US-6218432-B1 | FOR PROTECTING BODY AGAINST OXIDATIVE STRESS | L'OREAL (FR) | 2001-04-17 | — | — | US | claimed |
| US-5834518-A | FOR APPLICATION TO SKIN | L'OREAL (FR) | 1998-11-10 | — | — | US | claimed |
| US-20040039059-A1 | Use of n,n' -dibenzyl ethylene diamine-n, n'- diacetic acid derivatives as anti-pollution agent | L'OREAL (FR) | 2004-02-26 | — | — | US | disclosed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | disclosed |
| US-6482855-B2 | OXIDATION RESISTANCE; STRESS RELIEVING | L'OREAL S.A. (FR) | 2002-11-19 | — | — | US | disclosed |
| US-20010016592-A1 | Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | L'OREAL S.A. | 2001-08-23 | — | — | US | disclosed |
| US-6218432-B1 | FOR PROTECTING BODY AGAINST OXIDATIVE STRESS | L'OREAL (FR) | 2001-04-17 | — | — | US | disclosed |
| US-6005006-A | BLEACHING AND DEPIGMENTING COMPOUNDS FOR SKIN | L'OREAL (FR) | 1999-12-21 | — | — | US | disclosed |
| US-5985564-A | INHIBITOR OF CHROMOSOME SEGREGATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-11-16 | — | — | US | disclosed |
| US-5834518-A | FOR APPLICATION TO SKIN | L'OREAL (FR) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016592-A1 | Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | DDC, AADAC, AADAT | KDM4E 2559/4885ALDH1A1 100/4885MEN1 1477/4885 |
| US-20040039059-A1 | Use of n,n' -dibenzyl ethylene diamine-n, n'- diacetic acid derivatives as anti-pollution agent | DDT, NAA15, NDC1 | KDM4E 2983/4885ALDH1A1 820/4885MEN1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.